Integra LifeSciences and University of Pennsylvania to Present Results of Brain Tissue Oxygen Monitoring Clinical Experience at 2004 Congress of Neurological Surgeons Annual Meeting in San Francisco
PLAINSBORO, N.J., Oct. 18, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that the Department of Neurosurgery and Surgery, University of Pennsylvania is presenting the results of four clinical studies on the application of the LICOX® Brain Tissue Oxygen Monitoring system to the management of brain injured patients, including those with severe traumatic brain injury or subarachnoid hemorrhage (SAH), at the 2004 Congress of Neurological Surgeons Annual Meeting in San Francisco this week.
The key findings of these studies include the following:
- Conventional strategies consisting of intracranial pressure (ICP)
and cerebral perfusion pressure (CPP) management may result in
significant reductions in cerebral oxygenation despite what would
otherwise be considered adequate ICP and CPP.
- Management and therapy aimed at preventing cerebral hypoxia and
maintaining brain tissue oxygen is successful in reducing
mortality in traumatic brain injury.
- Occult cerebral hypoxia may be present in traumatic brain injury
patients undergoing routine neurocritical care despite traditional
measurements and practices to maintain cerebral perfusion.
- Brain tissue oxygen monitoring enhances understanding of cerebral
pathophysiology and helps improve ventilator management
strategies.
- Although nimodipine use is associated with improved outcome in
SAH, in some patients it can transiently reduce brain oxygen, and
nimodipine dosage may need to be adjusted in some SAH patients
based on their weight.
"We posit that with conventional neuro-monitoring, inadequate cerebral oxygenation may occur in some patients," said Peter D. LeRoux M.D., FACS, Associate Professor and Vice Chairman, Department of Neurosurgery, University of Pennsylvania. "Studies suggest that optimal ICP and CPP management may not always prevent cerebral ischemia and infarction. Because these conventional methods of neurocritical care monitoring sometimes fail to ensure cerebral oxygenation, new strategies should be pursued. Since we started using the LICOX® Brain Tissue Oxygen Monitoring System in 2002 we have found it to be a useful addition to existing neuromonitoring methods."
Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (http://www.Integra-LS.com).
CONTACT:
Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com
Maria Platsis
Director of Corporate Development and Investor Relations
(609) 936-2333
mplatsis@Integra-LS.com